IFNA1 and renal cell carcinoma: Patients with RCC were randomized 1:1 in an open label study to receive Nap+IFN-α or IFN-α: 15 μg/kg Nap was given intravenously in three cycles of four once daily injections plus IFN-α (9 MU subcutaneously three times weekly) or the same dose and schedule of IFN-α monotherapy.